Diabetes mellitus (DM), commonly known as diabetes, is a group of metabolic disorders characterized by a high blood sugar level over a prolonged period of time. Symptoms often include frequent urination, increased thirst, and increased appetite. If left untreated, diabetes can cause many complications. Acute complications can include diabetic ketoacidosis, hyperosmolar hyperglycemic state, or death. Serious long-term complications include cardiovascular disease, stroke, chronic kidney disease, foot ulcers, damage to the nerves, damage to the eyes and cognitive impairment.
Two newer types of drugs commonly used to treat type 2 diabetes are similar in their ability to reduce major heart complications, including heart attack, stroke and death from cardiovascular disease, according to research accepted for presentation at ENDO 2020, the Endocrine Society's annual meeting, and publication in a special supplemental section of the Journal of the Endocrine Society.
One class of drugs, known as SGLT2 inhibitors, has a clear benefit over the other class, known as GLP-1 drugs, in reducing hospitalization for heart failure, the study found.
SGLT2 inhibitors are prescription oral medications used to treat type 2 diabetes. (Tanzeum), dulaglutide (Trulicity), exenatide (Byetta), liraglutide (Victoza) and semaglutide (Ozempic).
In prior studies, it was found that these two classes of drugs showed heart and kidney benefits besides controlling the blood sugar.
The researchers analyzed data from six previous trials of GLP-1 (including a total of 51,762 subjects) and four trials of SLGT2 inhibitors (including 33,457 subjects) .Both drug classes were equally effective in reducing combined major adverse cardiac events such as heart attack, stroke and death from cardiovascular disease, compared to people with diabetes who were not taking the drugs.
The rate of hospitalization for heart failure was 32% less in patients taking SLT2 inhibitors compared to patients not taking the drugs, especially in those with more severe cardiovascular disease risk.In contrast, people taking GLP-1 drugs did not have a reduced rate of hospitalization for heart failure compared with people who had diabetes but were not taking the drugs.Both classes of drugs demonstrate kidney benefit; neither class was superior.
The most common serious side effects for SGLT2 inhibitors included yeast infections in women and diabetic ketoacidosis, a rare life-threatening problem that can affect people with diabetes.The major serious side effect for GLP-1 drugs was stomach upset.
“Doctors need to balance this side effect against the possible weight-loss benefits of this medicine,” Al-Khazaali said.
Type 2 diabetes is the most common form of diabetes.Semaglutide is an agonist of glucagon-like peptide-1 (GLP-1) receptor that is developed to treat type 2 diabetes.It reduces blood sugar via increasing the production of insulin.Biochempeg can provides some key intermediates of Semaglutide with high purity.
Peptide Modifications: Linkers, Spacers and PEGylation
Biochempeg is a biotechnology-oriented company in Watertown, Massachusetts.It provides custom PEGylated conjugates and PEGylation services for peptides, and small molecules.PEGylation is the process of covalently attaching polyethylene glycol (PEG) polymer chains to peptides.Safety And Effectiveness Of First-line Antihypertensive Drug Classes
This article is edited by Sonia Li who from Huateng Pharma.ADCs Effectively Targets Surface Protein Of Neuroblastoma In Children
This artile shows us ADCs can effectively targets surface protein of neuroblastoma in children.